SanegeneBio agreed commercial licenses with major pharma players for RNAi assets, with Genentech (Roche) paying $200 million upfront for at least one candidate and larger potential milestone payments and royalties cited. Sanegene positions its RNAi chemistry and delivery platforms as the basis for deals that hand early development to the biotech and transfer later clinical/commercial responsibilities to the pharma partner. Sanegene’s arrangements highlight renewed Big Pharma appetite for RNAi chemistries and targeted delivery, and follow a wave of recent partnerships and dealmaking in oligonucleotide therapeutics. Company statements noted plans for initial development by Sanegene with clinical advancement and global commercialization managed by Genentech/Roche, aligning incentives via milestone and royalty structures.